Research programme: iron chelators - MetaPhore
Latest Information Update: 27 May 2008
At a glance
- Originator MetaPhore Pharmaceuticals
- Class Iron compounds
- Mechanism of Action Chelating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Iron overload
Most Recent Events
- 02 Apr 2008 ActivBiotics sells its intellectual property assets including drug product candidates
- 29 Dec 1999 New profile
- 29 Dec 1999 Preclinical development for Iron overload in USA (Unknown route)